DESIGN, SYNTHESIS, AND EVALUATION OF NOVEL TYROSINASE INHIBITORS FOR SKIN DEPIGMENTATION
DOI:
https://doi.org/10.22159/ijap.2026v18i1.54475Keywords:
Tyrosinase inhibitors, Skin whitening, Molecular docking, In vitro assay, Cinnamic acid, DepigmentationAbstract
Objective: Hyperpigmentation is a prevalent dermatological condition caused by excessive melanin production, primarily catalyzed by the enzyme tyrosinase. Existing depigmenting agents, such as hydroquinone and kojic acid, are limited by cytotoxicity, instability, and suboptimal efficacy. This study aimed to design, synthesize, and evaluate structurally novel tyrosinase inhibitors derived from cinnamic acid to overcome these limitations.
Methods: Tencinnamic acid-based derivatives were designed with strategic modifications, including esterification with hydroquinone and aromatic moieties, to enhance binding affinity and stability. Molecular docking studies were conducted using tyrosinase crystal structures (PDB IDs: 3NQ1 and 5I38) to identify key binding interactions. Six lead compounds were synthesized and structurally characterized via NMR and FTIR spectroscopy. Their tyrosinase inhibitory activity was assessed in vitro using mushroom tyrosinase under standardized assay conditions.
Results: Molecular docking revealed favorable interactions within the tyrosinase active site, with compound 9 exhibiting the highest docking scores. In vitro assays confirmed compound 9 as the most potent inhibitor, with an IC₅₀ value of 31.35 µg/mL, outperforming kojic acid (IC₅₀ = 94.96 µg/mL) and hydroquinone (IC₅₀ = 772.8 µg/mL) under identical conditions.
Conclusion: Compound 9 demonstrated superior tyrosinase inhibition compared to conventional agents, indicating its potential as a safer and more effective alternative for treating hyperpigmentation. These findings support further development of compound 9 for use in topical formulations targeting melasma and related pigmentary disorders, with planned follow-up studies including in vivo efficacy and safety evaluations.
References
1. Ahlam Zaid Alkilani, et al. Batool Musleh, Rania Hamed, Lubna Swellmeen, Haneen A Basheer, Preparation and characterization of patch loaded with clarithromycin nanovesicles for transdermal drug delivery, Journal of functional biomaterials. 2023;14(2):57
2. Ainger SA, et al. Skin pigmentation genetics for the clinic. Dermatology. 2017;233(1):1–15.
3. Bergfelt DR. Anatomy and physiology of the mare. In: Equine breeding management and artificial insemination. 2009. p. 113–31.
4. Prakash V, Jaiswal N, Srivastava M. A review on medicinal properties of Centella asiatica. Asian J Pharm Clin Res. 2017;10(10):69–74.
5. Saadh MJ, et al. Advances in mesenchymal stem/stromal cell-based therapy and their extracellular vesicles for skin wound healing. Hum Cell. 2023;36(4):1253–64.
6. Betz G, et al. In vivo comparison of various liposome formulations for cosmetic application. Int J Pharm. 2005;296(1–2):44–54.
7. Yousef H, Alhajj M, Sharma S. Anatomy, skin (integument), epidermis. 2017.
8. Chakraborty AK, et al. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res. 1998;11(4):206–12.
9. LaBerge GS, et al. Recent advances in studies of skin color and skin cancer. Yale J Biol Med. 2020;93(1):69.
10. Sauriasari R, Azizah N, Basah K. Tyrosinase inhibition, 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity, and phytochemical screening of fractions and ethanol extract from leaves and stem bark of matoa (Pometia pinnata). Asian J Pharm Clin Res. 2017:85–9.
11. AlJbour ND. An overview of new trends in the cosmetics industry. Int J Appl Pharm. 2025;17(3):136–47.
12. Chang T-S. An updated review of tyrosinase inhibitors. Int J Mol Sci. 2009;10(6):2440–75.
13. Singh K, et al. Recent advances in enzyme inhibition: A pharmacological review. Curr Enzyme Inhib. 2024;20(1):2–19.
14. Kim H-D, et al. Naturally-occurring tyrosinase inhibitors classified by enzyme kinetics and copper chelation. Int J Mol Sci. 2023;24(9):8226.
15. Kim Y-J, Uyama H. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell Mol Life Sci. 2005;62:1707–23.
16. Melfi F, et al. Nature as a source and inspiration for human monoamine oxidase B (hMAO-B) inhibition: A review of the recent advances in chemical modification of natural compounds. Expert Opin Drug Discov. 2023;18(8):851–79.
17. Hajizadeh M, et al. An outlook on suicide enzyme inhibition and drug design. J Iran Chem Soc. 2022:1–18.
18. Sánchez‐Más J, et al. Agonist‐independent, high constitutive activity of the human melanocortin 1 receptor. Exp Dermatol. 2004;13(9):581.
19. Gajos-Michniewicz A, Czyz M. WNT signaling in melanoma. Int J Mol Sci. 2020;21(14):4852.
20. Liu T, et al. Research progress on pathogenesis of skin pigmentation in chronic liver disease. Biomol Biomed. 2025.
21. Nordlund J, Grimes P, Ortonne J-P. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781–7.
22. Kapoor DU, et al. Konjac glucomannan: A comprehensive review of its extraction, health benefits, and pharmaceutical applications. Carbohydr Polym. 2024:122266.
23. Rubab L, et al. Targeting Tyrosinase: Heterocyclic Compounds in the Spotlight. In: Heterocyclic Chemistry—New Perspectives. 2024. p. 45.
24. Gunia‐Krzyżak A, et al. Cinnamic acid derivatives in cosmetics: current use and future prospects. Int J Cosmet Sci. 2018;40(4):356–66.
25. Hassan M, Shahzadi S, Kloczkowski A. Tyrosinase inhibitors naturally present in plants and synthetic modifications of these natural products as anti-melanogenic agents: a review. Molecules. 2023;28(1):378.
26. Juliano CC. Spreading of dangerous skin-lightening products as a result of colourism: a review. Appl Sci. 2022;12(6):3177.
27. Kamboj S, et al. Recent advances in permeation enhancement techniques for transdermal drug delivery systems: a review. Curr Drug Ther. 2013;8(3):181–88.
28. Karkeszová K, Mastihubová M, Mastihuba V. Regioselective enzymatic synthesis of kojic acid monoesters. Catalysts. 2021;11(12):1430.
29. Elliott D, et al. ACCCN's critical care nursing. Elsevier Australia; 2011.
30. Al-Amin M, et al. Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation. Drug Des Devel Ther. 2016:3947–57.
31. Kabiri H, et al. Preparation, characterization, and evaluation of anti‐tyrosinase activity of solid lipid nanoparticles containing Undecylenoyl phenylalanine (Sepiwhite®). J Cosmet Dermatol. 2022;21(11):6061–71.
32. Hatem S, et al. Nano-vesicular systems for melanocytes targeting and melasma treatment: In-vitro characterization, ex-vivo skin retention, and preliminary clinical appraisal. Int J Pharm. 2024;665:124731.
33. Khan HMS, et al. Encapsulation of alpha arbutin, a depigmenting agent, in nanosized ethosomes: in vitro and in vivo human studies. Heliyon. 2023;9(9).
34. Huang X, et al. Transdermal BQ-788/EA@ ZnO quantum dots as targeting and smart tyrosinase inhibitors in melanocytes. Mater Sci Eng C. 2019;102:45–52.
35. Jeyranpour F, Alahyarizadeh G, Arab B. Comparative investigation of thermal and mechanical properties of cross-linked epoxy polymers with different curing agents by molecular dynamics simulation. J Mol Graph Model. 2015;62:157–65.
36. Abdullah AH, et al. Docking, synthesis, and anticancer assessment of novel quinoline-amidrazone hybrids. Pharmacia. 2024;71:1–12.
37. Wang Y-H, et al. Quantitative determination of α-arbutin, β-arbutin, kojic acid, nicotinamide, hydroquinone, resorcinol, 4-methoxyphenol, 4-ethoxyphenol, and ascorbic acid from skin whitening products by HPLC-UV. J AOAC Int. 2015;98(1):5–12.
38. Neeley E, et al. Variations in IC50 values with purity of mushroom tyrosinase. Int J Mol Sci. 2009;10(9):3811–23.
39. Phasha V, et al. Review on the use of kojic acid—A skin-lightening ingredient. Cosmetics. 2022;9(3):64.
40. Souza PM, et al. Plants from Brazilian Cerrado with potent tyrosinase inhibitory activity. PLoS One. 2012;7(11):e48589.
41. Mukattash, H. K, et al. Inhibitory Effects of Polyphenols from Equisetum ramosissimum and Moringa peregrina Extracts on Staphylococcus aureus, Collagenase, and Tyrosinase Enzymes: In vitro Studies. Jordan Journal of Pharmaceutical Sciences. 2024; 17(3), 530-548.
Published
How to Cite
Issue
Section
Copyright (c) 2025 AMANI Y. SALMAN, MANAL M. NAJDAWI, MAHMOUD A. AL-SHA’ER, NAWZAT D. AL JBOUR, RAWANDM DAGHMASH, ANWAR M. HUSSEIN, SULIMAN M. EDEAS, LOAY K. HASSOUNEH, ZEAD H. ABUDAYEH, ALA’ SARHAN, MOHAMMED ALKADERI
This work is licensed under a Creative Commons Attribution 4.0 International License.
